Literature DB >> 22926128

Surface plasmon resonance, fluorescence, and circular dichroism studies for the characterization of the binding of BACE-1 inhibitors.

Angela De Simone1, Francesca Mancini, Feliciana Real Fernàndez, Paolo Rovero, Carlo Bertucci, Vincenza Andrisano.   

Abstract

The mechanism of action underlying β-secretase 1 (BACE-1) inhibition was characterized by a surface plasmon resonance (SPR) method using primary amino groups to immobilize OM99-2, a well-known highly potent peptidic BACE-1 inhibitor, on the carboxyl groups of the dextran layer of a sensor chip. The diluted BACE-1 was mixed with buffer or the test compound and the mixture was flushed through the chip. BACE-1 binding to the immobilized peptide inhibitor was quantified. This SPR method was used to identify BACE-1 inhibitor binding sites and the mechanism of action (competitive/noncompetitive) and to validate findings of fluorescence resonance energy transfer (FRET) inhibition studies. To support this, a multimethodological approach (circular dichroism and fluorescence spectroscopy) was applied in parallel to FRET inhibition studies to characterize the binding modes of peptidic and nonpeptidic BACE-1 inhibitors. Circular dichroism spectroscopy served to correlate the conformation of BACE-1 with enzymatic activity and to monitor secondary structure changes upon ligand binding. In a complementary approach, direct fluorescence spectroscopy was used to characterize different BACE-1 inhibitor binding sites. The influence of pH and inhibitors on BACE-1 secondary structure was also elucidated. This multimethodological approach was applied to identify binding modes of bis(7)-tacrine and myricetin in comparison with well-known peptidic inhibitors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22926128     DOI: 10.1007/s00216-012-6312-0

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  2 in total

1.  Fragment Binding to β-Secretase 1 without Catalytic Aspartate Interactions Identified via Orthogonal Screening Approaches.

Authors:  Frederik J R Rombouts; Richard Alexander; Erna Cleiren; Alex De Groot; Michel Carpentier; Joyce Dijkmans; Katleen Fierens; Stefan Masure; Diederik Moechars; Martina Palomino-Schätzlein; Antonio Pineda-Lucena; Andrés A Trabanco; Daan Van Glabbeek; Ann Vos; Gary Tresadern
Journal:  ACS Omega       Date:  2017-02-24

2.  Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer's Disease β Secretase, BACE1.

Authors:  Courtney J Mycroft-West; Anthony J Devlin; Lynsay C Cooper; Scott E Guimond; Patricia Procter; Marco Guerrini; Gavin J Miller; David G Fernig; Edwin A Yates; Marcelo A Lima; Mark A Skidmore
Journal:  Mar Drugs       Date:  2021-04-03       Impact factor: 5.118

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.